3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
327
Neoplasm Metastasis
31
Advanced Breast Cancer
19
Neoplasms
17
Ovarian Neoplasms
11
Hereditary Sensory and Autonomic Neuropathies
10
Triple Negative Breast Neoplasms
8
Prostatic Neoplasms
7
Endometrial Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
6
Uterine Cervical Neoplasms
5
Breast Diseases
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms by Site
4
Colorectal Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Recurrence
3
Multiple Endocrine Neoplasia Type 1
3
Head and Neck Neoplasms
3
Breast Neoplasm Female
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Liposarcoma
2
Hyperglycemia
2
HER2-positive Metastatic Breast Cancer
2
HER2-positive Breast Cancer
2
Interventions
abemaciclib
1
Trastuzumab
1
Tablets
1
Genetic Testing
1
Fulvestrant
1
Everolimus
1
Blood Specimen Collection
1
Biomarkers
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hormone Receptor Positive Breast Cancer
×
Fulvestrant
×
Breast
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts